NXT-ID Authentication Using Face and Voice Recognition

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and identity product that is being developed by Shelton, Connecticutt-based NXT-ID, Inc. (OTCQB:NXTD).

NXT-ID was founded by former senior management at Technest Holidings and its subsidiary, Genex Technologies, industry-leading companies in the field of advanced imaging, including 3D and 360-degree technologies. NXT-ID has licensed these companies’ technologies, as well as technologies from 3D-imaging expert Geometrix. Utilizing these technologies with their own intellectual property, NXT-ID is launching MobileBio, a technology that secures consumers’ mobile platforms through authentication and encryption. As the trend continues to move towards mobile transactions, there is a great need for advanced solutions to protect users’ and institutions’ information more effectively than the inherently insecure standards of payment today. MobileBio is the cornerstone of NXT-ID’s end-to-end solutions to bridge the gap.

The company has developed Biocloud, a cloud-based biometric identify authentication solution for consumer applications and corporate security. The company’s MobileBio Voicematch platform can be bootstrapped to several platforms, such as smartphones, tablets and computers, to embed additional security via voice recognition biometrics to ensure the identity of a user before allowing access to countless applications. Voicematch is forecast to be available in the first quarter of 2014. Along the same lines, MobileBio Facematch employs modular facial recognition to devices for superior authentication and encryption. Several configurations are possible, including hosting the technology on a device or remotely in the cloud by marrying Facematch with Biocloud. According to NXT-ID, Facematch will soon be available in an app for iPhone and Android systems.

After Thursday’s closing bell, NXT-ID announced that it took the next step with its next-generation digital wallet, called the “Wocket.” The Wocket is being designed to reduce the number of cards in a person’s wallet while supporting essentially every payment method used today at retailers, such as magnetic stripe, barcodes, etc. all from a secure digital vault. The company said that it has successfully ported its MobileBio voicematch algorithm to the Wocket, which brings the product one move closer to commercialization.

“We are pleased with the continued development of the Wocket™,” says David Tunnell, CTO of NXT-ID. “Our approach eliminates the need for passwords by authenticating identity in a natural way for users. With Voicematch™, users can simply ask for a user-defined name of a card and the Wocket™ then automatically programs the NXTCard with the card of their choice.”

A lot of noise has been made recently about improving security on devices of all types. Apple (Nasdaq:AAPL) was even criticized for not including their thumbprint technology on the latest generation of iPhones 5C’s to prevent unauthorized use. While thumbprint technology is certainly a more advanced security feature and will be welcomed by the masses, what NXT-ID is taking things to the next level with voice and facial recognition. In short (and layman’s terms), this is some pretty cool stuff.

NXT-ID is an early-stage company that just went public in August via an S-1 registration, but interest seems to remain strong with shares climbing from initially around $1.50 to as high as $6.00 before pulling back to current levels around $3.50. As the products start rolling-out to the public, even more investors (and other companies) may start taking note of this upstart and the cutting-edge technology it possesses. Proper due diligence is, as always, encouraged.

NXT-ID, Inc. (NXTD) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at


Other articlesgo to homepage

Stocks Mixed on Monday

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

Cellceutix Targeting Gram-Negative and Candida Fungal Infections

Cellceutix Targeting Gram-Negative and Candida Fungal Infections(0)

Monday morning, Cellceutix Corp. (OTCQB: CTIX) provided shareholders with an update on its progress with filing an Investigational New Drug application with the FDA for its anti-psoriasis drug. Additionally - and taking the headline - the company delivered to shareholders news that it has made additional promising advancements with its pipeline to potentially address diseases

Catalyst Pharmaceutical Partners Stock Chart Analysis Video

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

EnteroMedics Stock Chart Analysis Video

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

Dow Not Tired of Making New Record Highs

Dow Not Tired of Making New Record Highs(0)

The Dow Jones Industrials will have to wait till at least next week to mount the lofty heights of 16,000 points, but both the Dow and the S&P did end the day at record highs. The Dow Jones Industrials was up 85.48 points from yesterday”s all-time high, to close at 15,961.70 The S&P 500 index

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.